OverviewSuggest Edit
DiaSorin is a company that produces and markets in vitro diagnostics reagent kits used in immunodiagnostics and molecular diagnostics. Its line of products used by diagnostic laboratories that are part of hospital facilities or operate independently can meet the needs of the following clinical areas: infectious diseases, cardiac markers, bone metabolism, hepatitis and retrovirus, oncology, and endocrinology. DiaSorin also provides life science products that have a range of applications including academic and scientific research, public health and food safety, plant pathogens detection and cell counts, viability, and cell health analyses.
| Type | Public | |
| Founded | 1968 | |
| HQ | Saluggia, IT | Map |
| Website | diasoringroup.com | |
| Employee Ratings | More |
Recent NewsAll News
- Global Lyme Alliance and DiaSorin Announce Partnership Seeking Study Volunteers to Advance an Innovative Lyme Disease Diagnostic
- DiaSorin Q2 Revenues Rise 20 Percent on SARS-CoV-2 Testing Demand
- Join the special DiaSorin’s Integrated Session during the 31st ECCMID
- DiaSorin announces completion of the acquisition of Luminex Corporation
Key People/Management at DiaSorin
Carlo Rosa
Chief Executive Officer
Gustavo Denegri
Chairman
Piergiorgio Pedron
Chief Financial Officer
Stefano Ronchi
Senior Corporate VP Human Resources
Ugo Gay
Senior Corporate Vice President Industrial Operations
Chen Even
Chief Commercial Officer
DiaSorin Office Locations
DiaSorin has offices in Saluggia, Italy, Cypress, Stillwater and in 20 other locations
Saluggia, IT (HQ)
Via Crescentino, snc
Italy, IT
Via Roberto Lepetit, 34
Saluggia, IT
via crescentino snc 13040
Macquarie Park, AU
11 Talavera Road
Wien, AT
Schottenring 16/Top 08-10A
Anderlecht, BE
Paapsemlaan & Boulevard Paepsem
DiaSorin Financials and Metrics
DiaSorin Revenue
DiaSorin's revenue was reported to be €881.31 m in FY, 2020
| EUR | |
|---|---|
Revenue (Q3, 2021) | 343.5m |
Gross profit (Q3, 2021) | 195.1m |
Net income (Q3, 2021) | 79.3m |
EBITDA (Q3, 2021) | 80.4m |
EBIT (Q3, 2021) | 109.9m |
Market capitalization (13-May-2022) | 6.5b |
Closing stock price (13-May-2022) | 119.1 |
EV | 6.5b |
DiaSorin's current market capitalization is €6.5 b.
Annual
| EUR | FY, 2018 | FY, 2019 | FY, 2020 |
|---|---|---|---|
Revenue | 669.2m | 706.3m | 881.3m |
Cost of goods sold | (162.6m) | (134.1m) | (219.6m) |
Gross profit | 507.9m | 572.2m | 661.7m |
R&D expense | (45.1m) | (47.9m) | (50.8m) |
Quarterly
| EUR | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 |
|---|---|---|---|---|---|---|---|---|---|
Revenue | 170.8m | 179.5m | 174.8m | 174.6m | 207.7m | 227.8m | 266.7m | 248.7m | 343.5m |
Cost of goods sold | (52.2m) | (25.7m) | (84.1m) | (54.0m) | (31.3m) | (105.1m) | (81.6m) | (49.0m) | (148.4m) |
Gross profit | 118.6m | 153.7m | 90.8m | 120.6m | 176.4m | 122.7m | 185.1m | 199.7m | 195.1m |
R&D expense | (11.7m) | (11.6m) | (11.1m) | (12.4m) | (13.1m) | (12.5m) | (23.5m) | (20.8m) |
Annual
| EUR | FY, 2018 | FY, 2019 | FY, 2020 |
|---|---|---|---|
Cash | 73.1m | 157.6m | 339.9m |
Accounts Receivable | 131.1m | 132.5m | 165.7m |
Inventories | 160.4m | 171.1m | 191.2m |
Quarterly
| EUR | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 |
|---|---|---|---|---|---|---|---|---|---|
Cash | 90.1m | 138.7m | 896.8m | ||||||
Accounts Receivable | 136.3m | 158.2m | 158.4m | ||||||
Inventories | 167.5m | 195.3m | 203.0m |
Annual
| EUR | FY, 2018 | FY, 2019 | FY, 2020 |
|---|---|---|---|
Net Income | 158.1m | 175.7m | 248.3m |
Depreciation and Amortization | 50.8m | 59.0m | 58.8m |
Inventories | (14.4m) | (9.8m) | (30.2m) |
Accounts Payable | (8.6m) | (1.8m) | 11.0m |
Quarterly
| EUR | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | 84.0m | 94.7m | 157.6m | 150.0m | 339.9m | ||||
Depreciation and Amortization | 29.2m | 30.0m | 29.5m | ||||||
Inventories | (7.3m) | (29.4m) | (20.0m) | ||||||
Accounts Payable | (5.3m) | 6.5m | 13.4m |
| EUR | FY, 2018 |
|---|---|
Revenue/Employee | 339.5k |
DiaSorin Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Luminex | April 11, 2021 | $1.8 b |
DiaSorin Revenue Breakdown
DiaSorin revenue breakdown by business segment: 100.0% from HEALTH CARE DIVERSIFIED
Human Capital Metrics
DiaSorin's employees are reported to be approximately 45% female and 55% male.
DiaSorin Cybersecurity Score
DiaSorin Environment, Social & Governance (ESG) Ratings
DiaSorin Online and Social Media Presence
789 Twitter followers
DiaSorin has 789 Twitter Followers. The number of followers has decreased 0.2% month over month and increased 0.9% quarter over quarter
DiaSorin's Trends
DiaSorin News and Updates
September 21, 2021
Global Lyme Alliance and DiaSorin Announce Partnership Seeking Study Volunteers to Advance an Innovative Lyme Disease Diagnostic
Today, Global Lyme Alliance (GLA) and DiaSorin, a global leader in the laboratory diagnostics market specializing in the immunodiagnostics and molecular diagnostics segments, announce a partnership to raise awareness of DiaSorin’s LIAISON LymeDetect® study.
July 30, 2021
DiaSorin Q2 Revenues Rise 20 Percent on SARS-CoV-2 Testing Demand
DiaSorin said on Friday that its second quarter revenues rose 20 percent year over year, driven by strength in molecular diagnostic test sales.
July 15, 2021
Join the special DiaSorin’s Integrated Session during the 31st ECCMID
DiaSorin’s Integrated Session during the 31st ECCMID, the European Congress of ESCMID - European Society of Clinical Microbiology and Infectious Diseases, on “Diagnosis and immune response of SARS-CoV-2-infection” with the participation of international experts.
July 14, 2021
DiaSorin announces completion of the acquisition of Luminex Corporation
DiaSorin S.p.A. (“DiaSorin”; FTSE MIB: DIA) announces it has completed the acquisition of Luminex Corporation (“Luminex”; NASDAQ: LMNX) for a price of USD 37.00 per share that corresponds to a total equity value of approximately USD 1.8 billion.
June 05, 2021
Today we report our Q1 2021 results
Today we report our Q1 2021 results - Significant growth in Revenues and Profitability, Strong Operating Cash Flow Generation and Record Net Financial Position
April 12, 2021
DiaSorin to acquire Luminex Corporation for USD 37.00 per share or approximately USD 1.8 billion
DiaSorin S.p.A. ("DiaSorin"; FTSE MIB: DIA) today announced that its Board of Directors has unanimously approved and signed a definitive merger agreement for DiaSorin to acquire Luminex Corporation ("Luminex";NASDAQ: LMNX) for a price of USD 37.00 per share in an all-cash transaction. This correspon…
DiaSorin Blogs
May 09, 2022
DiaSorin and B·R·A·H·M·S, part of Thermo Fisher Scientific, partner to develop and commercialize the new LIAISON® B·R·A·H·M·S MR-proADM™
Mon, 05/09/2022 - 07:02
pdfDownload press release173.49KB
Add to print basket
Go to print basket
Add to bookmarks
Add note
Go to note basket
Send to friend
Italiano
May 06, 2022
Strong growth in revenues and cash flow generation in Q1 2022
Saluggia (Italy), May 6, 2022 - The Board of Directors of DiaSorin S.p.A. (FTSE MIB: DIA), a global leader in the research, production and marketing of diagnostic tests and internationally active in the Life Science sector, meeting today examined and approv…
May 06, 2022
Strong growth in revenues and cash flow generation in Q1 2022 - Full Year 2022 Guidance revised upwards
Fri, 05/06/2022 - 16:45
pdfDownload press release304.04KB
Add to print basket
Go to print basket
Add to bookmarks
Add note
Go to note basket
Send to friend
Italiano
April 26, 2022
Report on the remuneration policy for the year 2022 and remuneration paid in the year 2021
Language
English
Thu, 04/07/2022 - 18:10
Allegati:
pdfDownload file924.14KB
Add to print basket
Go to print basket
Add to bookmarks
Add note
Go to note basket
Send to friend
Italiano
April 22, 2022
New proposal for resolution related to the remuneration of the Board of Statutory Auditors
Fri, 04/22/2022 - 12:37
pdfDownload file281.82KB
Add to print basket
Go to print basket
Add to bookmarks
Add note
Go to note basket
Send to friend
Italiano
April 13, 2022
DiaSorin: Publication of the updated proxy forms for voting through the Designated Representative
Wed, 04/13/2022 - 16:43
pdfDownload file282.86KB
Add to print basket
Go to print basket
Add to bookmarks
Add note
Go to note basket
Send to friend
Italiano
DiaSorin Frequently Asked Questions
When was DiaSorin founded?
DiaSorin was founded in 1968.
Who are DiaSorin key executives?
DiaSorin's key executives are Carlo Rosa, Gustavo Denegri and Piergiorgio Pedron.
How many employees does DiaSorin have?
DiaSorin has 2,104 employees.
What is DiaSorin revenue?
Latest DiaSorin annual revenue is €881.3 m.
What is DiaSorin revenue per employee?
Latest DiaSorin revenue per employee is €418.9 k.
Who are DiaSorin competitors?
Competitors of DiaSorin include OpGen, Akonni Biosystems and Cisbio.
Where is DiaSorin headquarters?
DiaSorin headquarters is located at Via Crescentino, snc, Saluggia.
Where are DiaSorin offices?
DiaSorin has offices in Saluggia, Italy, Cypress, Stillwater and in 20 other locations.
How many offices does DiaSorin have?
DiaSorin has 25 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies